Webinar summary: How to generate
liquidity in the pharmaceutical sector
COST-SAVING MECHANISMS IN THE PHARMACEUTICAL SECTOR
The pharmaceutical sector is one of the great economic dynamizers of our country and one of the sectors with the greatest opportunities when it comes to generating liquidity, the problem occurs when these savings instruments are unknown by the companies in the sector.
For this reason, and in order to present some of the mechanisms that allow companies in the pharmaceutical sector to save costs and develop scientific advances through public financing instruments, on November 17 we held a webinar focused on how to generate liquidity in the pharmaceutical sector.
The session began with the presentation of some of the national tax incentives that pharmaceutical companies can benefit from. Our colleague María Victoria Palau, Key Account Manager of the Innovation unit was in charge of presenting some of these instruments, such as R&D tax deductions or cash-back. María Victoria, who has more than 16 years of experience in the management and execution of innovation projects, also explained other benefits such as the economic interest groupings and the advantages of the structure of this instrument, as well as the activation of R&D expenses and the Patent Box, which allows to complete the financing of innovative projects through a reduction of up to 60% of the taxation of income derived from the assignment or transfer of certain intangible assets.
Horizon Europe: grants for drug development
Halfway through the session, our colleague Óscar Salazar, Technical Manager of European Funds, took over to explain in detail what the participation of a company in a European project consists of. During his speech, Oscar, who has more than 15 years of experience in basic research and development in the pharmaceutical and biotechnology industry, indicated what will be the novelties of the European framework program Horizon Europe for the period 2021-2027. On the other hand, our colleague focused on the health program of this line of public funding.
Finally, Oscar presented IMI2, a joint initiative between the European Union, represented by the Commission, and the European Federation of Pharmaceutical Industries and Associations with the aim of accelerating the development of better and safer medicines.
In Euro-Funding we develop funding maps for each project by analyzing the different public calls for grants and credits at regional, state and European level. Our technical team analyzes the investment plans to develop a customized financing scenario.